Pharmos pain drug fails in Phase II

Shares of Pharmos dropped this morning after researchers announced that a mid-stage trial of its experimental therapy for intravenous pain failed to hit its primary endpoint. The trial studied the response of 24 patients to cannabinor. A separate test for relieving pain associated with molar dental extractions will continue. "While we are disappointed that cannabinor did not show efficacy in this pain model, we have a newly developed oral formulation of cannabinor targeting chronic neuropathic pain with repeated administration," said Dr. Haim Aviv, chairman & CEO. "We plan to move forward with the program for orally administered cannabinor, and our next step is to conduct a Phase I safety trial in healthy volunteers."

- here's the release on the clinical trial

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.